Sernova Corp. Stock price Toronto S.E.

Equities

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Delayed Toronto S.E. 11:59:16 2024-03-28 am EDT 5-day change 1st Jan Change
0.55 CAD -1.79% Intraday chart for Sernova Corp. -1.75% -20.00%
Sales 2024 * 8M 5.9M Sales 2025 * - Capitalization 170M 125M
Net income 2024 * -38M -28.02M Net income 2025 * -30M -22.12M EV / Sales 2024 * 18.3 x
Net cash position 2024 * 23.61M 17.41M Net cash position 2025 * 17.72M 13.06M EV / Sales 2025 * -
P/E ratio 2024 *
-6.22 x
P/E ratio 2025 *
-4.67 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.46%
More Fundamentals * Assessed data
Dynamic Chart
Sernova Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Sernova Corp. Announces CFO Changes CI
Sernova Corp. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA MT
Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System? at the 2023 IPITA-IXA-CTRMS Joint Congress CI
Sernova Announces Positive Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial MT
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System? for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress CI
Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting CI
Sernova Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device CI
Sernova Names New CEO, Former CEO Assumes Tech Chief Role MT
Sernova Corp. Announces Executive Changes CI
Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer CI
Sernova Corp Appoints Modestus Obochi as Chief Business Officer CI
Sernova Corp. Reports Updated Interim Phase 1/2 Clinical Data for Cell Pouch System at American Diabetes Association Meet MT
More news
1 week-1.75%
Current month-6.67%
1 month-9.68%
3 months-15.15%
6 months-28.21%
Current year-20.00%
More quotes
1 week
0.54
Extreme 0.54
0.59
1 month
0.53
Extreme 0.53
0.63
3 years
0.51
Extreme 0.51
2.22
5 years
0.10
Extreme 0.095
2.87
10 years
0.10
Extreme 0.095
2.87
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-04
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 21-06-29
Members of the board TitleAgeSince
Director/Board Member 58 12-04-18
Chief Tech/Sci/R&D Officer - 09-04-27
Director/Board Member - 22-09-29
More insiders
Date Price Change Volume
24-03-28 0.55 -1.79% 35 167
24-03-27 0.56 +1.82% 85,630
24-03-26 0.55 0.00% 28,000
24-03-25 0.55 -5.17% 110,454
24-03-22 0.58 +3.57% 30,800

Delayed Quote Toronto S.E., March 28, 2024 at 09:30 am EDT

More quotes
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.56 CAD
Average target price
4.15 CAD
Spread / Average Target
+641.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Sernova Corp.
  4. Stock Sernova Corp. - Toronto S.E.